Cargando…

Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1

Re-education of the tumor microenvironment with immune checkpoint inhibitors (ICI) has provided the most significant advancement in cancer management, with impressive efficacy and durable response reported. However, low response rates and a high frequency of immune-related adverse events (irAEs) rem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacquot, Perrine, Muñoz-Garcia, Javier, Fleury, Maurine, Cochonneau, Denis, Gaussin, Rémi, Enouf, Elise, Roze, Caroline, Ollivier, Emilie, Cinier, Mathieu, Heymann, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135760/ https://www.ncbi.nlm.nih.gov/pubmed/37189383 http://dx.doi.org/10.3390/biom13040636

Ejemplares similares

Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFR(pos) Mouse Xenograft Model
por: Huet, Simon, et al.
Publicado: (2023)

Use of the Nanofitin Alternative Scaffold as a GFP-Ready Fusion Tag
por: Huet, Simon, et al.
Publicado: (2015)

Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation
por: Garlich, Joshua, et al.
Publicado: (2022)

Lipopolysaccharide-binding protein expression is associated to the metastatic status of osteosarcoma patients
por: Heymann, Clément J.F., et al.
Publicado: (2022)

Technical report: liquid overlay technique allows the generation of homogeneous osteosarcoma, glioblastoma, lung and prostate adenocarcinoma spheroids that can be used for drug cytotoxicity measurements
por: Jubelin, Camille, et al.
Publicado: (2023)

Three-dimensional in vitro culture models in oncology research
por: Jubelin, Camille, et al.
Publicado: (2022)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020)

Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma
por: Jubelin, Camille, et al.
Publicado: (2022)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
por: Huang, Manley T. F., et al.
Publicado: (2022)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression
por: Sun, Jisan, et al.
Publicado: (2018)

Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
por: Redhead, Martin A., et al.
Publicado: (2021)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains
por: Benedetti, Filippo, et al.
Publicado: (2021)

Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
por: Yanakieva, Desislava, et al.
Publicado: (2022)

The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis
por: Muñoz-Garcia, Javier, et al.
Publicado: (2021)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
por: Kühl, Lennart, et al.
Publicado: (2023)

Tuning Relative Polypeptide Expression to Optimize Assembly, Yield and Downstream Processing of Bispecific Antibodies
por: Magistrelli, Giovanni, et al.
Publicado: (2018)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells
por: Soto-Gamez, Abel, et al.
Publicado: (2020)

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
por: Lum, Lawrence G, et al.
Publicado: (2015)

Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
por: Redhead, Martin A., et al.
Publicado: (2021)

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
por: Qiao, Guilin, et al.
Publicado: (2022)

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
por: Park, Jeong A, et al.
Publicado: (2022)

Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine
por: Tellez-Gabriel, Marta, et al.
Publicado: (2018)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies
por: Goulet, Dennis R., et al.
Publicado: (2018)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
por: Mohan, Nishant, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t0gl096ujjbppe845724djog7b